Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
STAT+
Health
Biotech
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Biotech
STAT+

KKR veteran sets records with $3.9 billion health care fund

  • Allison DeAngelis

By Allison DeAngelis Feb. 1, 2023

Reprints
Jim Momtazee helped start and lead KKR’s health care team for nearly two decades before launching Patient Square Capital. Courtesy Katherine Smith

The former head of health care investing at private equity giant KKR has set records with the first fundraising for his new firm.

The firm, Patient Square Capital, closed on $3.9 billion for its fund Wednesday. That makes it the largest inaugural fund for a new U.S.-based private equity firm. The previous record was set by Centerbridge Partners’ $3.2 billion fundraising in 2006, according to data from PitchBook.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Allison DeAngelis

Allison DeAngelis

Biotech Startups and Venture Capital Reporter

Allison DeAngelis is a biotech reporter at STAT, covering biopharma startups and venture capital.

Tags

Create a display name to comment

This name will appear with your comment

Researchers devise new strategies to overcome a key CRISPR…
Researchers devise new strategies to overcome a key CRISPR flaw
Top FDA official: Agency needs to start using accelerated…
Top FDA official: Agency needs to start using accelerated approval for gene therapies
‘Three Identical Strangers’: It’s not too late to address…
‘Three Identical Strangers’: It’s not too late to address the ethical violations
Key senators blast Medicare Advantage insurers for ‘exorbitant salaries,’…
Key senators blast Medicare Advantage insurers for ‘exorbitant salaries,’ ‘massive payouts’ to execs
FDA advisory panel recommends conditional approval of Biogen’s drug…
FDA advisory panel recommends conditional approval of Biogen’s drug for rare form of ALS
Drugmakers push back on a clever tactic employers use…
Drugmakers push back on a clever tactic employers use to avoid paying for specialty medicines

Recommended Stories